Q2 2024 Medpace Holdings Inc Earnings Call Transcript
Key Points
- Revenue for the second quarter of 2024 was $528.1 million, representing a year-over-year increase of 14.6%.
- EBITDA for the second quarter increased by 34.2% to $112.3 million, with an EBITDA margin of 21.3%.
- Net income for the second quarter increased by 44.7% to $88.4 million, with net income per diluted share rising to $2.75.
- Ending backlog as of June 30, 2024, was approximately $2.9 billion, an increase of 13.7% from the prior year.
- Medpace Holdings Inc (MEDP) raised its 2024 EPS guidance, reflecting confidence in future growth and profitability.
- Net new business awards entering backlog decreased by 4.1% from the prior year to $551 million, influenced by higher cancellations.
- Cancellations were disproportionately high in June, impacting the net book-to-bill ratio, which stood at 1.04.
- The company anticipates a depressed book-to-bill ratio in Q3 due to the elevated cancellations in Q2.
- Customer concentration remains a concern, with the top 5 and top 10 customers representing roughly 22% and 29% of year-to-date revenue, respectively.
- The company did not repurchase any shares during the second quarter, despite having $308.8 million remaining under its share repurchase authorization program.
Good day, ladies and gentlemen, and welcome to Medpace's second-quarter 2024 earnings conference Call. (Operator Instructions) . As a reminder, this call may be recorded.
I would now like to introduce your host for today's conference call. Lauren Morris, Medpace's Director of Investor Relations. You may begin.
Good morning, and thank you for joining Medpace's second-quarter 2024 earnings conference call. Also on the call today is our CEO, August Troendle; our President, Jesse Geiger; and our CFO, Kevin Brady.
Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve inherent assumptions with known and unknown risks and uncertainties, as well as other important factors that could cause actual results to differ materially from our current expectations. These factors are discussed in our Form 10-K
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
